自拟润肠通便汤加减联合常规西药对老年慢性传输型便秘患者的效果观察

马剑海

doi:10.3969/j.issn.1671-038X.2019.09.08

自拟润肠通便汤加减联合常规西药对老年慢性传输型便秘患者的效果观察

马剑海^,

- 秦皇岛市中医医院肛肠科, 河北秦皇岛 066000

详细信息

作者简介:
马剑海,男,本科,研究方向:中西结合肛肠,中西医结合治疗便秘

通讯作者: 马剑海,E-mail:918245868@qq.com

中图分类号: R256.35

收稿日期: 2019-05-15

Observation on the effect of self-made Runchangtongbian decoction addition and subtraction combined with routine western medicine on senile patients with chronic transit constipation

MA Jian-hai^,

- Department of Proctology, Qinhuangdao Hospital of Traditional Chinese Medicine, Qinhuangdao 066000, China

More Information

Corresponding author: MA Jian-hai, E-mail: 918245868@qq.com

Received Date: 15 May 2019

摘要

摘要: [目的]观察自拟润肠通便汤加减联合常规西药对老年慢性传输型便秘患者的效果。[方法]将94例老年慢性传输型便秘患者选为受试对象, 以随机数表分为西药组和联合组, 各47例。西药组给予常规西药 (莫沙必利+金双歧) 治疗, 联合组在西药组的基础上联合自拟润肠通便汤加减治疗, 均治疗2周。对比治疗前后结肠传输功能试验结果和便秘症状评分变化, 临床疗效, 治疗前后生活质量评分变化, 不良反应。[结果]治疗后2组结肠内存留的标志物数目均减少 (P<0.05), 便秘症状和生活质量评分均下降 (P<0.05), 且治疗后联合组结肠内存留的标志物数目少于西药组 (P<0.05), 便秘症状和生活质量评分均低于西药组 (P<0.05);联合组临床疗效分布与西药组差异显著 (P<0.05), 前者总有效率高达100.00%, 远高于后者的85.11% (P<0.05);联合组不良反应发生率为10.64%, 稍高于西药组的4.26%, 2组间差异无统计学意义 (P>0.05)。[结论]对老年慢性传输型便秘患者给予自拟润肠通便汤加减联合常规西药可显著减轻症状, 增强疗效, 改善生活质量, 且不会显著增加不良反应风险。
- 润肠通便 /
- 西药 /
- 老年人 /
- 慢性传输型便秘
Abstract: [Objective]To observe the effect of self-made Runchangtongbian decoction addition and subtraction combined with routine Western medicine on senile patients with chronic transit constipation.[Methods]Ninety-four elderly patients with chronic transit constipation were selected as subjects and randomly divided into Western medicine group and combined group, 47 cases each.Western medicine group was treated with conventional Western medicine (mosapride + live combined bifidobacterium).On the basis of Western medicine group, the combined group was treated with self-made Runchangtongbian decoction addition and subtraction, both for 2 weeks.The results of colonic transit function test and constipation symptom score before and after treatment, clinical efficacy, quality of life score before and after treatment, adverse reactions were compared.[Results]After treatment, the numbers of colon markers in both groups decreased (P<0.05), the symptoms of constipation and quality of life scores decreased (P<0.05), and the number of colon markers in the combined group was less than that in the Western medicine group (P<0.05), and the scores of constipation symptoms and quality of life were lower than those in the Western medicine group (P<0.05).The clinical efficacy distribution of the combined group was significantly different from that of the Western medicine group (P<0.05).The total effective rate of the former group was as high as 100.00%, which was much higher than that of 85.11% in the latter group (P<0.05).The incidence of adverse reactions in the combined group was 10.64%, slightly higher than that of 4.26% in the Western medicine group, and there was no significant difference between the two groups (P>0.05).[Conclusion]The self-made Runchangtongbian decoction addition and subtraction combined with conventional Western medicine can significantly alleviate symptoms, enhance curative effect and improve the quality of life in elderly patients with chronic transit constipation, without significantly increasing the risk of adverse reactions.
- runchangtongbian /
- western medicine /
- elderly /
- chronic transit constipation

HTML全文

参考文献(16)

[1]	De Marco P, Militello G, Tutino R, et al.The management of the slow transit constipation in the laparoscopic era[J].G Chir, 2018, 34 (5):297-302.
[2]	中国便秘联谊会, 中国医师协会肛肠分会.2017版便秘的分度与临床策略专家共识[J].中华胃肠外科杂志, 2018, 21 (3):345-345.
[3]	李超男, 龚雨萍.慢传输型便秘用药规律的文献研究[J].江苏中医药, 2018, 50 (1):73-75.
[4]	霍黎生, 臧亮, 孙龙, 等.大黄附子汤对脾肾阳虚型慢传输型便秘大鼠排便功能的影响研究[J].现代中西医结合杂志, 2017, 26 (2):128-130.
[5]	张东旭, 朱安龙.慢传输型便秘的发病机制与诊治[J].中华胃肠外科杂志, 2016, 19 (12):1447-1450.
[6]	陈园桃.中医病证诊疗常规[M].南京:东南大学出版社, 2008:182-189.
[7]	袁庆延.慢性便秘患者报告临床结局 (CC-PRO) 评估量表在中医治疗中的应用[D].南京中医药大学, 2016.
[8]	金洵, 丁义江, 丁曙晴, 等.便秘患者生存质量自评量表PAC-QOL中文版的信度、效度及反应度[J].世界华人消化杂志, 2011, 19 (2):209-213.
[9]	Nakajima A, Seki M, Taniguchi S, et al.Safety and efficacy of elobixibat for chronic constipation:results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial[J].Lancet Gastroenterol Hepatol, 2018, 3 (8):537-547.
[10]	Heemskerk SCM, Rotteveel AH, Benninga MA, et al.Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation:study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis[J].Int J Colorectal Dis, 2018, 33 (4):493-501.
[11]	Ghoshal UC.Chronic constipation in Rome IV era:The Indian perspective[J].Indian J Gastroenterol, 2017, 36 (3):163-173.
[12]	赖江, 李春霄.钟以泽教授治疗结肠慢传输型便秘临床经验介绍[J].四川中医, 2018, 36 (1):20-22.
[13]	姚秋园, 于永铎, 付原琰.慢传输型便秘与血瘀的实验研究[J].吉林中医药, 2017, 37 (2):170-173.
[14]	王亨飞.苁蓉通便汤治疗阳虚便秘临床观察[J].中医药临床杂志, 2018, 30 (6):1147-1150.
[15]	孙秀娟.麻仁软胶囊治疗老年便秘的疗效观察[J].中草药, 2018, 49 (11):2629-2631.
[16]	陈莉, 王东强, 李志军, 等.中西医结合四联疗法治疗麻痹性肠梗阻的临床疗效观察[J].中国中西医结合急救杂志, 2017, 24 (1):36-39.